{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:30:20Z","timestamp":1792197020536,"version":"4.4.0"},"reference-count":71,"publisher":"American Diabetes Association","issue":"12","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P30DK056350-23"],"award-info":[{"award-number":["P30DK056350-23"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01 AG071663"],"award-info":[{"award-number":["R01 AG071663"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["T32 AG01914"],"award-info":[{"award-number":["T32 AG01914"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Sarcopenic obesity, a subtype of obesity, is marked by reduced skeletal muscle mass and function, or sarcopenia, and poses a significant health challenge to older adults as it affects an estimated 28.3% of people aged &amp;gt;60 years. This subtype is unique to older adults as aging exacerbates sarcopenia and obesity due to changes in energy metabolism, hormones and inflammatory markers, and lifestyle factors. Traditional treatments for sarcopenic obesity have been focused on exercise and dietary modifications to reduce fat while maintaining muscle mass. Newer glucagon-like peptide 1 receptor agonists (GLP-1RAs) and dual gastric inhibitory polypeptide\/GLP-1 receptor agonists (GIP\/GLP-1RAs), including liraglutide, semaglutide, and tirzepatide, have shown great promise to reduce weight, treat obesity-related complications, improve physical function, and improve quality of life, in younger clinical trial populations. However, the use of GLP-1RAs and GIP\/GLP-1RAs has not been exhaustively evaluated in older adults with sarcopenic obesity. These medications come with the risk of loss of muscle mass and an increased rate of adverse events. Thus, clinicians should use them cautiously by weighing the potential benefits against their risks. Herein, we discuss a possible approach to using GLP-1RAs and GIP\/GLP-1RAs in patients with sarcopenic obesity, including considerations for patient identification, monitoring, maintenance, and discontinuation. In this article we also discuss the emerging treatments that will be available, which may include activin type II receptor antibodies and selective androgen receptor agonists. We conclude by highlighting the advancement of geroscience as a promising field for individualizing treatments in the future.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Article Highlights<\/jats:title>\n                    <jats:p>Sarcopenic obesity, reduced muscle mass and strength coupled with obesity, poses significant health risks to older adults. Aging exacerbates sarcopenia and obesity due to metabolic, hormonal, inflammatory, and lifestyle changes. Traditional interventions emphasize exercise and diet to reduce fat mass while preserving muscle mass. Incretin therapies show promise in weight reduction and physical improvement in younger populations but are minimally studied in older adults. These medications can be used to treat several obesity-related complications, which older adults with sarcopenic obesity are prone to developing. These medications need to be used cautiously among older adults, considering potential muscle mass loss and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title\/>\n                  <\/jats:sec>","DOI":"10.2337\/dbi25-0004","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T16:44:20Z","timestamp":1752252260000},"page":"2179-2190","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":34,"title":["Treating Sarcopenic Obesity in the Era of Incretin Therapies: Perspectives and Challenges"],"prefix":"10.2337","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1049-9274","authenticated-orcid":false,"given":"Alissa S.","family":"Chen","sequence":"first","affiliation":[{"name":"National Clinician Scholars Program, Yale School of Medicine 1 , New Haven, CT"},{"name":"Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine 2 , New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0845-4416","authenticated-orcid":false,"given":"John A.","family":"Batsis","sequence":"additional","affiliation":[{"name":"Division of Geriatric Medicine and Center for Aging and Health, University of North Carolina at Chapel Hill 3 , Chapel Hill, NC"},{"name":"Department of Nutrition, Gillings School of Global Public Health, University of North Carolina at Chapel Hill 4 , Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"2026061115180714200_B1","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","article-title":"Projected U.S. state-level prevalence of adult obesity and severe obesity","volume":"381","author":"Ward","year":"2019","journal-title":"N Engl J Med"},{"key":"2026061115180714200_B2","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/obr.12815","article-title":"Treatment of obesity in older persons-a systematic review","volume":"20","author":"Haywood","year":"2019","journal-title":"Obes Rev"},{"key":"2026061115180714200_B3","article-title":"The conceptual definition of sarcopenia: Delphi consensus from the Global Leadership Initiative in Sarcopenia (GLIS)","volume":"5","author":"Kirk","year":"2024","journal-title":"Age Ageing"},{"key":"2026061115180714200_B4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.clnu.2023.02.018","article-title":"Sarcopenic obesity research perspectives outlined by the sarcopenic obesity global leadership initiative (SOGLI) - proceedings from the SOGLI consortium meeting in rome November 2022","volume":"42","author":"Gortan Cappellari","year":"2023","journal-title":"Clin Nutr"},{"key":"2026061115180714200_B5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41574-018-0062-9","article-title":"Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies","volume":"14","author":"Batsis","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"2026061115180714200_B6","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/jgs.12260","article-title":"Variation in the prevalence of sarcopenia and sarcopenic obesity in older adults associated with different research definitions: dual-energy X-ray absorptiometry data from the National Health and Nutrition Examination Survey 1999-2004","volume":"61","author":"Batsis","year":"2013","journal-title":"J Am Geriatr Soc"},{"key":"2026061115180714200_B7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13395-022-00309-5","article-title":"The prevalence of low muscle mass associated with obesity in the USA","volume":"12","author":"Murdock","year":"2022","journal-title":"Skelet Muscle"},{"key":"2026061115180714200_B8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41574-023-00943-z","article-title":"Sarcopenic obesity in older adults: a clinical overview","volume":"20","author":"Prado","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"2026061115180714200_B9","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3945\/ajcn.2008.26847","article-title":"Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults","volume":"89","author":"Flegal","year":"2009","journal-title":"Am J Clin Nutr"},{"key":"2026061115180714200_B10","first-page":"405","article-title":"Muscle tissue changes with aging","volume":"7","author":"Volpi","year":"2004","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"2026061115180714200_B11","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/sj.ijo.0801251","article-title":"Appetite after weight loss by energy restriction and a low-fat diet-exercise follow-up","volume":"24","author":"Doucet","year":"2000","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2026061115180714200_B12","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/ajcn\/88.4.906","article-title":"Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight","volume":"88","author":"Rosenbaum","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"2026061115180714200_B13","doi-asserted-by":"crossref","first-page":"204164","DOI":"10.1155\/2013\/204164","article-title":"Sarcopenic obesity and endocrinal adaptation with age","volume":"2013","author":"Sakuma","year":"2013","journal-title":"Int J Endocrinol"},{"key":"2026061115180714200_B14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fphys.2015.00012","article-title":"The regulation of muscle mass by endogenous glucocorticoids","volume":"6","author":"Braun","year":"2015","journal-title":"Front Physiol"},{"key":"2026061115180714200_B15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ypmed.2016.05.009","article-title":"Prevalence and trends in physical activity among older adults in the United States: a comparison across three national surveys","volume":"89","author":"Keadle","year":"2016","journal-title":"Prev Med"},{"key":"2026061115180714200_B16","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1161\/01.CIR.0000074229.93804.5C","article-title":"Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase","volume":"107","author":"Hambrecht","year":"2003","journal-title":"Circulation"},{"key":"2026061115180714200_B17","doi-asserted-by":"crossref","DOI":"10.1152\/japplphysiol.00123.2005","article-title":"Exercise-induced increase in muscle insulin sensitivity","volume":"99","author":"Holloszy","year":"2005","journal-title":"J Appl Physiol (1985)"},{"key":"2026061115180714200_B18","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1113\/jphysiol.2011.225003","article-title":"Muscle protein synthesis in response to nutrition and exercise","volume":"590","author":"Atherton","year":"2012","journal-title":"J Physiol"},{"key":"2026061115180714200_B19","doi-asserted-by":"crossref","DOI":"10.1152\/japplphysiol.00592.2021","article-title":"Insulin-like growth factor-I biocompartmentalization across blood, interstitial fluid and muscle, before and after 3 months of chronic resistance exercise","volume":"133","author":"Sterczala","year":"2022","journal-title":"J Appl Physiol (1985)"},{"key":"2026061115180714200_B20","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3945\/ajcn.111.020800","article-title":"A moderate acute increase in physical activity enhances nutritive flow and the muscle protein anabolic response to mixed nutrient intake in older adults","volume":"95","author":"Timmerman","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"2026061115180714200_B21","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1186\/s12889-022-13288-5","article-title":"Associations of physical activity with sarcopenia and sarcopenic obesity in middle-aged and older adults: the Louisiana Osteoporosis Study","volume":"22","author":"Du","year":"2022","journal-title":"BMC Public Health"},{"key":"2026061115180714200_B22","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1111\/j.1467-789X.2010.00769.x","article-title":"A systematic review of environmental factors and obesogenic dietary intakes among adults: are we getting closer to understanding obesogenic environments?","volume":"12","author":"Giskes","year":"2011","journal-title":"Obes Rev"},{"key":"2026061115180714200_B23","doi-asserted-by":"crossref","first-page":"510801","DOI":"10.1155\/2012\/510801","article-title":"Nutrition and sarcopenia: a review of the evidence and implications for preventive strategies","volume":"2012","author":"Robinson","year":"2012","journal-title":"J Aging Res"},{"key":"2026061115180714200_B24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s13679-023-00509-0","article-title":"Effects of nutrition and exercise interventions on persons with sarcopenic obesity: an umbrella review of meta-analyses of randomised controlled trials","volume":"12","author":"Reiter","year":"2023","journal-title":"Curr Obes Rep"},{"key":"2026061115180714200_B25","doi-asserted-by":"crossref","first-page":"913953","DOI":"10.3389\/fendo.2022.913953","article-title":"Exercise and physical performance in older adults with sarcopenic obesity: a systematic review","volume":"13","author":"Ghiotto","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026061115180714200_B26","doi-asserted-by":"crossref","DOI":"10.3390\/nu11092163","article-title":"Effects of exercise and nutritional intervention on body composition, metabolic health, and physical performance in adults with sarcopenic obesity: a meta-analysis","volume":"11","author":"Hsu","year":"2019","journal-title":"Nutrients"},{"key":"2026061115180714200_B27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/jgs.14514","article-title":"Weight loss interventions in older adults with obesity: a systematic review of randomized controlled trials since 2005","volume":"65","author":"Batsis","year":"2017","journal-title":"J Am Geriatr Soc"},{"key":"2026061115180714200_B28","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/gerona\/glp007","article-title":"Moderate exercise attenuates the loss of skeletal muscle mass that occurs with intentional caloric restriction-induced weight loss in older, overweight to obese adults","volume":"64","author":"Chomentowski","year":"2009","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2026061115180714200_B29","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1007\/s12603-018-1139-9","article-title":"International clinical practice guidelines for sarcopenia (ICFSR): screening, diagnosis and management","volume":"22","author":"Dent","year":"2018","journal-title":"J Nutr Health Aging"},{"key":"2026061115180714200_B30","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa1008234","article-title":"Weight loss, exercise, or both and physical function in obese older adults","volume":"364","author":"Villareal","year":"2011","journal-title":"N Engl J Med"},{"key":"2026061115180714200_B31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/nutrit\/nuv065","article-title":"Effects of dietary protein intake on body composition changes after weight loss in older adults: a systematic review and meta-analysis","volume":"74","author":"Kim","year":"2016","journal-title":"Nutr Rev"},{"key":"2026061115180714200_B32","doi-asserted-by":"crossref","first-page":"200127","DOI":"10.1016\/j.hnm.2021.200127","article-title":"Barriers to healthy lifestyle behaviours and adherence to physical activity and dietary guidelines by older Australians: a descriptive analysis","volume":"25","author":"Gadowski","year":"2021","journal-title":"Hum Nutr Metab"},{"key":"2026061115180714200_B33","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.clnu.2020.10.001","article-title":"Long-term effect of bariatric surgery on body composition in patients with morbid obesity: a systematic review and meta-analysis","volume":"40","author":"Haghighat","year":"2021","journal-title":"Clin Nutr"},{"key":"2026061115180714200_B34","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1007\/s11695-016-2102-7","article-title":"Bariatric surgery outcomes in sarcopenic obesity","volume":"26","author":"Mastino","year":"2016","journal-title":"Obes Surg"},{"key":"2026061115180714200_B35","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.diabres.2007.01.007","article-title":"Comparison of different methods to assess body composition of weight loss in obese and diabetic patients","volume":"77","author":"Ritz","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"2026061115180714200_B36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"2026061115180714200_B37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"2026061115180714200_B38","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"2026061115180714200_B39","article-title":"Efficacy of antiobesity medications for weight reduction in older adults: a systematic review","author":"Chen","journal-title":"Obesity (Silver Spring)."},{"key":"2026061115180714200_B40","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","year":"2024","journal-title":"Nat Med"},{"key":"2026061115180714200_B41","first-page":"49","article-title":"Tirzepatide-induced weight loss is associated with body composition improvements across age groups","volume":"30","author":"Kushner","year":"2022","journal-title":"Obesity (Silver Spring)"},{"key":"2026061115180714200_B42","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2026061115180714200_B43","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"2026061115180714200_B44","doi-asserted-by":"crossref","first-page":"bvae164","DOI":"10.1210\/jendso\/bvae164","article-title":"Fundamental body composition principles provide context for fat-free and skeletal muscle loss with GLP-1 RA treatments","volume":"8","author":"Tinsley","year":"2024","journal-title":"J Endocr Soc"},{"key":"2026061115180714200_B45","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1111\/dom.15620","article-title":"Effect of semaglutide 2.4\u2009mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: patient-reported outcomes from the STEP 1-4 trials","volume":"26","author":"Rubino","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026061115180714200_B46","doi-asserted-by":"crossref","first-page":"e12310","DOI":"10.1111\/cob.12310","article-title":"Validation of a new measure of quality of life in obesity trials: impact of weight on quality of life-lite clinical trials version","volume":"9","author":"Kolotkin","year":"2019","journal-title":"Clin Obes"},{"key":"2026061115180714200_B47","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026061115180714200_B48","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"2026061115180714200_B49","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","article-title":"Once-weekly semaglutide in persons with obesity and knee osteoarthritis","volume":"391","author":"Bliddal","year":"2024","journal-title":"N Engl J Med"},{"key":"2026061115180714200_B50","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMra1514009","article-title":"Mechanisms, pathophysiology, and management of obesity","volume":"376","author":"Heymsfield","year":"2017","journal-title":"N Engl J Med"},{"key":"2026061115180714200_B51","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/jdi.13773","article-title":"Efficacy and safety of once-weekly semaglutide in Japanese individuals with type\u20092 diabetes by baseline age and body mass index","volume":"13","author":"Yabe","year":"2022","journal-title":"J Diabetes Investig"},{"key":"2026061115180714200_B52","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.clnu.2021.11.014","article-title":"Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement","volume":"41","author":"Donini","year":"2022","journal-title":"Clin Nutr"},{"key":"2026061115180714200_B53","unstructured":"Zepbound [package insert]\n          . U.S. Food and Drug Administration. Accessed 1 March 2025. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217806s003lbl.pdf"},{"key":"2026061115180714200_B54","unstructured":"Wegovy [package insert]\n          . U.S. Food and Drug Administration. Accessed 1 March 2025. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215256s011lbl.pdf"},{"key":"2026061115180714200_B55","unstructured":"Saxenda [package insert]\n          . U.S. Food and Drug Administration. Accessed 1 March 2025. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/206321s016lbl.pdf."},{"key":"2026061115180714200_B56","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2024-335593","article-title":"Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders","volume":"96","author":"De Giorgi","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026061115180714200_B57","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S0140-6736(24)00351-9","article-title":"Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials","volume":"403","author":"Shi","year":"2024","journal-title":"Lancet"},{"key":"2026061115180714200_B58","doi-asserted-by":"crossref","DOI":"10.1111\/obr.12143","article-title":"Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule","volume":"15","author":"Heymsfield","year":"2014","journal-title":"Obes Rev"},{"key":"2026061115180714200_B59","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1017\/S000711452000224X","article-title":"Effects of gradual weight loss v. rapid weight loss on body composition and RMR: a systematic review and meta-analysis","volume":"124","author":"Ashtary-Larky","year":"2020","journal-title":"Br J Nutr"},{"key":"2026061115180714200_B60","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/ijo.2013.83","article-title":"Risk of symptomatic gallstones and cholecystectomy after a very-low-calorie diet or low-calorie diet in a commercial weight loss program: 1-year matched cohort study","volume":"38","author":"Johansson","year":"2014","journal-title":"Int J Obes (Lond)"},{"key":"2026061115180714200_B61","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy weight loss maintenance with exercise, liraglutide, or both combined","volume":"384","author":"Lundgren","year":"2021","journal-title":"N Engl J Med"},{"key":"2026061115180714200_B62","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/CIRCULATIONAHA.107.185650","article-title":"Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association","volume":"116","author":"Nelson","year":"2007","journal-title":"Circulation"},{"key":"2026061115180714200_B63","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/oby.24067","article-title":"Nutritional considerations with antiobesity medications","volume":"32","author":"Almandoz","year":"2024","journal-title":"Obesity (Silver Spring)"},{"key":"2026061115180714200_B64","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/dom.14551","article-title":"Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss","volume":"24","author":"Wharton","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2026061115180714200_B65","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"2026061115180714200_B66","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2337\/dci23-0100","article-title":"Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition?","volume":"47","author":"Locatelli","year":"2024","journal-title":"Diabetes Care"},{"key":"2026061115180714200_B67","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1146\/annurev-med-043021-014919","article-title":"New frontiers in obesity treatment: GLP-1 and nascent nutrient-stimulated hormone-based therapeutics","volume":"74","author":"Jastreboff","year":"2023","journal-title":"Annu Rev Med"},{"key":"2026061115180714200_B68","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1080\/14656566.2019.1622093","article-title":"Current pharmacotherapies for sarcopenia","volume":"20","author":"Hardee","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"2026061115180714200_B69","doi-asserted-by":"crossref","first-page":"e2033457","DOI":"10.1001\/jamanetworkopen.2020.33457","article-title":"Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial","volume":"4","author":"Heymsfield","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026061115180714200_B70","unstructured":"Veru announces positive topline data from phase 2b QUALITY clinical study: Enobosarm preserved lean mass in patients receiving WEGOVY (semaglutide) for weight reduction, 2025. Accessed 22 March 2025. Available from https:\/\/ir.verupharma.com\/news-events\/press-releases\/detail\/225\/veru-announces-positive-topline-data-from-phase-2b-quality"},{"key":"2026061115180714200_B71","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1556\/2060.105.2018.4.32","article-title":"Advances and challenges in geroscience research: an update","volume":"105","author":"Yabluchanskiy","year":"2018","journal-title":"Physiol Int"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/74\/12\/2179\/836727\/dbi250004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/74\/12\/2179\/836727\/dbi250004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:18:21Z","timestamp":1781205501000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/74\/12\/2179\/160535\/Treating-Sarcopenic-Obesity-in-the-Era-of-Incretin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":71,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,7,11]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dbi25-0004","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]}}}